Advanced glycation end product receptors (AGERs) play distinct functional roles in both the toxicity and disposal of advanced glycation end products (AGEs), substances that are linked to diabetes and aging. Overexpression of AGER1 in murine mesangial cells (MCs) (MC-R1) inhibited AGE-induced MAPK1,2 phosphorylation and NF-B activity and also increased AGE degradation. The mechanism of the inhibitory effects of AGER1, upstream of MAPK, was explored in MCs and HEK293 AGER1-expressing cells. AGEinduced Ras activation was found to be linked to Shc͞Grb2 complex formation and Shc phosphorylation in MCs, responses that were markedly reduced in MC-R1 cells. AGE responses also included EGF receptor (EGFR) phosphorylation in MCs or HEK293 cells, but this link was blocked in both MC-R1 and HEK293-R1 cells. Coexpression of AGER1 and EGFR in HEK293 cells decreased AGE-mediated EGFR and p44͞p42 phosphorylation but not EGF-induced p44͞p42 activation. AGE, S100͞calgranulin, or H 2O2 promoted MAPK phosphorylation in EGFR ؉ cells in a manner that was inhibitable by an EGFR inhibitor, AG1478. Also, in AGER1 cells, AGE-induced H2O2 formation and AGE-or S100-induced p44͞p42 phosphorylation were suppressed, and these effects were restored by R1 siRNA. These data confirm that R1 negatively regulates AGE-mediated oxidant stress-dependent signaling via the EGFR and Shc͞Grb2͞Ras pathway. AGER1 could serve as a model for developing therapeutic targets against vascular and kidney disorders related to diabetes and aging.
I
ncreased levels of advanced glycation end products (AGEs), generated by the nonenzymatic reaction of amino groups and reducing sugars, have been implicated in several chronic diseases characterized by sustained oxidant stress (OS) and multiorgan low-level inflammatory injury, including diabetes-related cardiovascular and renal disease, as well as aging (1) (2) (3) . At the cellular level, the damaging effects of AGE have been attributed to several AGE-binding proteins, most notably to RAGE (receptor for AGE), as well as others, including, but not limited to, AGE receptor (AGER) 1, R2, and R3 and the scavenger receptors class A type II (MSR-AII) and class B type I (MSR-BI, CD36) (4-7). These receptors have been shown to play distinct functional roles in AGE toxicity or AGE detoxification. Although RAGE is known to mediate cellular OS and inflammatory effects through the activation of the Ras-MAPK pathway, some receptors may have other functions [e.g., in AGE disposal (8) (9) (10) ].
AGER1, an Ϸ50-kDa type A integral membrane protein with a short internal domain, a single transmembrane segment, and a long intracellular tail, was initially isolated with other members of the oligosaccharyltransferase complex and was later found to be active in AGE-specific ligand binding and degradation (11) . Low expression of AGER1 in the kidneys of nonobese diabetic mice was associated with high tissue AGE levels and with kidney disease (12) . Human circulating mononuclear cells from diabetic subjects also show an association between low expression of AGER1 and high serum AGE along with severe diabetic complications (13) . Recently, we found that overexpression of AGER1 in mouse mesangial cells (MCs) led to inhibition of AGE-and RAGE-induced MAPK phosphorylation and NF-B activity (9) , suggesting that AGER1 may mitigate AGE-induced cellular toxicity. The purpose of this study was to elucidate the mechanism by which this property of AGER1 is mediated.
AGE, by means of reactive oxygen species (ROS) generation, could stimulate multiple receptors, including the EGF receptor (EGFR) (14, 15) . EGFR belongs to a large family of tyrosine kinase receptors and is involved in the regulation of multiple cellular processes, such as cell growth, motility, differentiation, survival, and death (16) . The EGFR binds many growth factors, including EGF, heparin-binding EGF, transforming growth factor-␣, amphiregulin, neuroregulin, ␤-cellulin, and epiregulin (17) . Ligand-triggered activation of its intrinsic tyrosine kinase and autophosphorylation of its tyrosine residues induces Ras-MAPK1,2 phosphorylation through activation of the Grb2͞Shc͞ Sos complex (18) (19) (20) . ROS may also block EGFR dephosphorylation, possibly by inhibition of protein-tyrosine phosphatase activity (21, 22) . AGE can generate ROS, in part through RAGE (15) , but there has been no direct evidence that AGE can interact with EGFR or with the Grb2͞Shc͞Sos complex. Therefore, we investigated whether AGE induces EGFR phosphorylation and, if so, what is the mechanism of induction. We then examined the effect of AGER1 overexpression on the AGE-induced EGFR pathway of activation.
We found that Shc͞Grb2 and EGFR phosphorylation are induced by AGE in WT MCs and kidney epithelium-like cells (HEK293) but are markedly attenuated by overexpressing AGER1. The observations provide vital mechanistic information about this previously uncharacterized AGE͞OS negative regulatory pathway, which may be important in AGE͞OS homeostasis.
Results

Overexpression of AGER1 Leads to Down-Regulation of AGE-Induced
Ras Activation and of Shc͞Grb2 Complex Formation. MCs and HEK293 cells were stably transfected with a V 5 -tagged vector encoding AGER1 at its C terminus (V 5 -AGER1), and, after enrichment by antibiotic selection, they were assessed by Western blot analysis using anti-V 5 antibody. The V 5 -AGER1 protein was overexpressed in both transfected cell types but not in mock transfectants or WT cells (Fig. 1) . Because Ras activation occurs upstream of MAPK1,2 phosphorylation, we investigated whether Ras activity was altered in AGER1-overexpressing and mock MCs after stimulation with AGE-BSA (50 and 200 g͞ml, respectively) for 15 min. Using a Ras activation assay, Ras activation was found to be blocked by AGER1 overexpression in MC-R1 cells when compared with MC-mock at both concentrations of AGE-BSA (P Ͻ 0.05) (Fig. 2) . As a control, native BSA did not affect Ras activation in either MC-R1 or MC-mock cells (Fig. 2) . Activation of Ras occurs as a result of Shc͞Grb2 complex formation. Therefore, the Shc͞Grb2 complex was assessed by immunoprecipitation with anti-Grb2 antibody followed by immunoblotting (IB) with anti-Shc antibody in MC-R1 and MC-mock cells after AGE stimulation. We found that, in mock cells, AGE-BSA increased Shc͞Grb2 complex formation, as shown by coimmunoprecipitation, whereas Shc͞Grb2 was completely blocked in MC-R1 cells (P Ͻ 0.05) (Fig. 3) . Again, EGF activation of Shc was preserved, suggesting that there was not a competitive interaction between the AGE and EGF ligands.
AGE-Induced Shc Phosphorylation Is Reduced in AGER1-Expressing
Cells. Because Shc͞Grb2 complex formation was significantly lower in AGER1-overexpressing cells, we examined Shc phosphorylation. Tyrosine phosphorylation of Shc protein was determined by using anti-phospho-Shc (Y317) antibody, because Y317 tyrosine phosphorylation has been shown to cause MAPK activation through Grb2 and Sos (23). AGE stimulation of MC-mock cells markedly enhanced Shc 52 tyrosine phosphorylation between 5 min (P Ͻ 0.01) and 15 min (P Ͻ 0.05) of stimulation (Fig. 4) . However, in 293-R1 cells, there was significantly less phosphorylated Shc 52 after stimulation with the same amount of AGE (P Ͻ 0.05). Total Shc protein levels did not change between 293-mock and 293-R1 cells.
EGFR Tyr Phosphorylation Is Blocked After AGE Stimulation, but Not
After EGF Stimulation, in HEK293-R1-Expressing Cells. Because Shc is recruited to phospho-residues of growth factor receptors [e.g., EGFR (24)], we tested the effect of AGE on phosphorylation of EGFR. We found that AGE caused EGFR phosphorylation in both HEK293 and HEK293-R1 cells (Fig. 5A ). In addition, we observed a striking difference in the levels of EGFR Tyr phosphorylation between HEK293-mock and HEK293-R1 cells in response to AGE-BSA. EGFR was maximally Tyr phosphorylated at 5 min in HEK293-mock cells, whereas it was attenuated in HEK293-R1 cells (Fig. 5A ). Of note, this suppressed response to AGE was somewhat recovered or counterbalanced after (293) were transfected with V 5-tagged full-length human cDNA encoding AGER1. Cell lysates from these stable cell lines were subjected to Western blotting by using anti-V 5 antibody as described.
cotransfection of 293-R1 cells with EGFR ( Fig. 5 A and B, right blots), suggesting a dependence on receptor availability. However, when, instead of AGE, EGF was used as a stimulant, neither EGFR protein expression nor phosphorylation levels differed between HEK293-R1 and mock cells ( (Fig. 6E) , providing further confirmation of a direct association between EGFR and AGER1.
AGE-Induced p44͞p42 Phosphorylation Is Constant After Overexpressing EGFR but Not After Coexpressing AGER1 and EGFR. HEK293-mock or EGFR ϩ cells were stimulated by AGE (200 g͞ml for 15 min); S100, a RAGE ligand agonist (5 g͞ml for 15 min); or H 2 O 2 (0.1 mM for 15 min) in the presence or absence of the EGFR-specific tyrosine phosphorylation inhibitor AG1478 (10 M). All three stimulants caused rapid MAPK phosphorylation (Fig. 7A) , which was not further increased after EGFR overexpression. These data were consistent with EGFR activation because this phosphorylation was largely blocked by AG1478 (Fig. 7B) . However, when AGER1 was coexpressed in 293-EGFR ϩ cells, AGE and S100-mediated MAPK phosphorylation was abolished (Fig. 7C ) but not when a more potent ROS source, H 2 O 2 , was used. Furthermore, the suppression of AGE and S100 was restored by silencing R1 by using siRNA (Fig. 7C) , confirming the fact that the inhibitory effects depended on the presence of AGER1.
AGE-Induced ROS Generation Is Suppressed in R1-Expressing Cells.
After incubation of 293-mock cells to AGE (200 g͞ml for 4 h), intracellular ROS (measured as H 2 O 2 ) increased significantly but not after exposure to BSA (Fig. 8) . In contrast, in R1-expressing cells, AGE-induced ROS generation was inhibited, suggesting that AGER1 negatively regulates ROS generation, the latter being a potent stimulus for EGFR phosphorylation. To assess whether EGFR activation indirectly influences AGE- induced ROS generation, 293-mock and R1-expressing cells were pretreated with AG1478 for 2 h before exposure to AGE (200 g͞ml for 4 h), and ROS were measured as above. AG1478 did not alter AGE-induced ROS generation in either mock or R1-expressing cells, indicating that EGFR activation does not contribute to AGE-mediated OS (Fig. 8) .
To further assess whether enhanced AGE clearance is responsible for reduced ROS in AGER1 cells, ROS production by AGE was assessed after inhibiting endocytosis by using phenylarsine oxide (PAO). PAO partially reversed the inhibitory effect of AGER1 on ROS generation in R1-expressing cells, possibly due to a blockade of AGE endocytosis and degradation in these cells (data not shown).
Discussion
AGER1 may play a protective role in the AGE-induced cellular toxicity that is seen in diabetes and aging by enhancing AGE disposal and by countering RAGE-promoted OS and subsequent MAPK͞NF-B-dependent cell activation (9, 12, 13) . In the present report, we found that EGFR and the Shc͞Grb2 complex have a previously unidentified role in the AGE signaling activation pathway. The negative regulatory effects of AGER1 on AGE signaling are mediated by means of the inhibition of EGFR phosphorylation and Shc͞Grb2 complex formation. These effects may be related to a direct molecular interaction between AGER1 and EGFR. AGER1 also exhibits significant suppressive effects on intracellular ROS generation, which may in part be due to increased AGE degradation by AGER1.
We found that AGE causes Ras͞MAPK1,2 activation by means of tyrosine phosphorylation of EGFR in two different types of kidney cells, MCs and epithelial (HEK293) cells. This interaction, as with the S100͞RAGE interaction, depends on the generation of ROS. The mechanism by which AGE induces ROS generation, resulting in Ras͞MAPK1,2 phosphorylation, remains unclear, because no AGERs, including RAGE, have known autophosphorylation sites or specific kinase activity (15, 25) .
ROS and H 2 O 2 are known triggers of Tyr phosphorylation of EGFR, which leads to downstream MAPK or Akt activation (26, 27) . Importantly, this can happen in the absence of EGF stimulation. As with H 2 O 2 , here, AGE and S100 also induced Tyr phosphorylation of EGFR. Because the EGFR activation inhibitor AG1478 inhibited the p44͞42 Tyr phosphorylation induced by all three ROS-triggering ligands, these inhibitions appeared to act via an EGFR-specific signal pathway. However, when the cells overexpressing EGFR were also transfected with AGER1, only AGE-and S100-induced p44͞42 Tyr phosphorylation was inhibited, and not that due to H 2 O 2 . Thus, AGER1 can counteract some of the downstream effects of AGE and S100 stimulation, both of which are ROS generators. Although the data do not suggest a direct interaction of either R1 or EGFR with RAGE, such a possibility requires further study. However, the findings remain consistent with a dependence of RAGE signaling on ROS and with a lack of specificity for AGE. In addition, AGER1 did not counteract exogenous H 2 O 2 -induced MAPK phosphorylation, indicating that this phosphorylation involves a different mechanism.
Activation of Ras occurs through GDP͞GTP exchange, catalyzed by the guanine nucleotide-exchange factor Sos proteins, which are translocated to the plasma membrane as a result of (29) . After undergoing phosphorylation, Shc provides higher affinity docking sites for Grb2 complex formation (24) . Shc phosphorylation usually occurs after Grb2 complex recruitment to phosphotyrosine residues of growth factors such as EGFR (24) . We found that AGE-mediated Ras and MAPK1,2 activation (30) progressed in a stepwise fashion through the EGFR-triggered sequence of events described above. Although we have not explored all of the relationships in this proximal phase of AGE signal induction, we noted that brief exposure to AGE preferentially stimulates Tyr phosphorylation of the 52-kDa Shc and, to a lesser extent, the 46-kDa Shc, but not the 66-kDa Shc, in kidney epithelial and MC lines. These studies made use of an anti-phosphotyrosine antibody that is specific for Tyr-317. In several cell types, EGFR activation involves all three Shc isoforms (31), including tyrosine and serine͞threonine phosphorylation. Thus, further studies are needed to determine whether these discrepancies are due to differences in the cell types or in the immunoreagents used. Based on previous reports that have linked phosphorylation of Shc 66 to EGFR inactivation (31), its possible role in AGER1-AGE signaling inactivation is worthy of further investigation (31) .
Shc͞Grb2 complex formation (28)
Our findings suggest that EGFR is an important contributor to the AGE cell activation pathway and also reveal a potential mechanism by which AGE signal suppression can limit AGE toxicity after AGER1 overexpression.
Interestingly, AGER1 overexpression did not affect EGFinduced signaling. Instead, EGF stimulation led to enhanced EGFR protein expression and signaling, remaining independent of the inhibitory action of AGER1. This observation suggests that AGER1 does not interfere with EGFR gene regulation and events induced by EGF [i.e., dimerization, adaptor recruitment, or signaling (16)]. Rather, the AGER1 effects on EGFR activity appear to be AGE͞ROS-specific. In fact, AGER1-mediated inhibition of AGE-induced EGFR activation (32, 33) was restored by R1 siRNA. Furthermore, AGE-induced intracellular ROS generation was inhibited in AGER1-overexpressing cells, supporting the pivotal role of AGER1 in this interaction.
Although AGE has been shown to stimulate heparin-binding EGF production (34) , the relationship that we found between AGERs and EGFR has not been suggested previously. The present studies clearly demonstrate a direct interaction between AGER1 and EGFR, although the molecular domains and the possibility that additional cellular components are involved in this interaction remain to be further explored. A possible dependence of EGFR responsiveness on the level of EGFR vs. R1 cell surface availability was suggested during EGFR and AGER1 single expression and coexpression studies. These data may point to a potential explanation for the low efficacy of AGER1 (12) under conditions of sustained ROS generation [e.g., in diabetes, when EGFR expression and activity might be expected to be elevated (32, 33) ].
Our previous report showed that AGER1 played a role in AGE clearance by mediating enhanced AGE uptake and degradation (9) . In the current study, we found that AGE-induced ROS levels in 293-R1 cells were no different from mock cells after partial blockade of endocytosis with the endocytosis inhibitor PAO. This observation indicated that, when AGER1 is overexpressed, it may more effectively clear AGE, causing attenuation of AGE͞ROS-mediated signaling, and that this finding could serve in part as an additional mechanism for reduced EGFR phosphorylation in R1 cells (35, 36) . However, a nonspecific PAO action could not be ruled out. Also, these data do not account for AGE ROS that are generated in cell types lacking AGE-specific endocytosis, and further studies are needed to address this issue in greater detail, including mapping of the AGER1-binding site and͞or of sites of interaction with EGFR.
Based on these findings, we speculate that, in a normal environment, AGER1 may sequester EGFR, the end result being to minimize undue EGFR activation by uncoupling EGFR from Shc͞Grb2͞Sos and Ras, thereby preventing inappropriate cell activation. Under conditions of sustained excess of AGE and ROS, however, the AGE-saturated AGER1 may be rendered inactive and no longer accessible to EGFR. Thus, excess ROS could lead to sustained EGFR and MAPK͞NF-B stimulation, which may account in part for an ineffective AGER1 function in chronic unregulated oxidant or carbonyl stress (e.g., in diabetes and age-related vascular͞renal diseases, also known as inflammatory states).
In conclusion, our findings help elucidate aspects of both the positive and negative regulatory steps of AGE-and AGERmediated activation pathways involved in the inflammatory response. Although we studied murine or human kidney cells, the data may apply to other cells and tissues that are shown to express AGER1. These data may improve the understanding by which AGE-caused cell toxicity can be regulated and could serve as a guide for developing therapeutic targets for vascular and kidney disorders related to diabetes and aging.
Materials and Methods
Materials. Anti-EGFR and Ras activation assay kits were obtained from Upstate Biotechnology (Lake Placid, NY). Anti-phosphotyrosine antibody PY20 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to Shc and Grb2 were obtained from BD Biosciences Transduction Laboratories (San Jose, CA). The expression vector containing WT human EGFR under the control of a CMV promoter was obtained from Upstate Biotechnology. Antibody to MAPK1,2 was purchased from New England BioLabs (Beverly, MA). Anti-V 5 antibody was from Invitrogen (Carlsbad, CA). S100 was from Calbiochem (San Diego, CA). There was no cross-reaction between anti-V 5 and EGFR, or anti-EGFR and R1, or between other reagents used. EGFR inhibitor AG1478 was from Calbiochem. N-acetylcysteine and hydrogen peroxide (H 2 O 2 ) were obtained from Sigma (St. Louis, MO), as was the endocytosis inhibitor PAO. Endotoxin-free AGE-BSA was prepared from endotoxin-free, lyophilized BSA (fraction IV; Sigma) and glucose as described in ref. 37 after extensive dialysis and passing through a filter (0.22-M pore size; Millipore, Billerica, MA). An endotoxin-binding affinity column (Pierce, Rockford, IL) was used to remove endotoxin from AGE-BSA and native BSA (tested by a Limulus amebocyte lysate assay; Bio Whittaker, Walkerville, MD).
Cell Culture. Human embryonic kidney epithelium-like cells (HEK293 or 293) were chosen because EGFR has been extensively studied in these cells (38) (39) (40) . Mouse MCs were identical to those used in our recent AGER1 studies (9) . MCs (CRL-1927; American Type Culture Collection) were maintained in DMEM͞F12 medium (3:1) containing 100 units͞ml penicillin, 100 g͞ml streptomycin, 14 mmol͞liter Hepes, and 5% FBS. HEK293 cells (CRL-1573; American Type Culture Collection) were maintained in MEM supplemented with 2 mM L-glutamine͞100 units/ml penicillin͞100 g/ml streptomycin͞10% FBS. Both cell lines were cultured at 37°C under a humidified atmosphere (5% CO 2 and 95% air). Before treatment, cells were washed with PBS and incubated with serumfree media for 12 h (quiescent cells). The addition of native BSA (300 g͞ml) under serum starvation conditions produced no discernible changes in cell reactivity.
Stable Expression of AGER1 in MCs and HEK293 Cells. Stable MC and 293 cell lines expressing human AGER1 protein were obtained after transfection of cells with a pcDNA3.1 (Invitrogen) vector containing a V 5 -tagged AGER1 construct (V 5 -AGER1) and subsequently selected by culturing cells in the presence of the neomycin analogue G418 (1 mg͞ml) (Invitrogen) for at least 3 weeks before use (9). G418-resistant cells containing
